Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

y participants were encouraging. Genzyme expects to release

results by mid year for a larger number of patients, including results

for those patients who have completed the one year trial. Final

results for all trial participants will be available in the first

quarter of 2009. Genzyme is currently developing clinical trial

protocols for two Phase 3 studies of Genz-112638, and the company

anticipates initiating these studies early next year. Genzyme believes

that this oral product may offer a more convenient treatment option for

some patients.

Mipomersen for high-risk cardiovascular disease

Genzyme expects to finalize its license of mipomersen from Isis

Pharmaceuticals in the second quarter and subsequently communicate a

development plan for the product. Mipomersen is a lipid-lowering agent

being developed primarily for patients at significant cardiovascular

risk who are unable to achieve target cholesterol levels with statins

alone or who are intolerant of statins. The product offers an

innovative approach to addressing a serious unmet medical need, and

Genzyme believes it could prove to be the most effective lipid-lowering

agent for high risk cardiovascular disease patients for whom

conventional therapies are not sufficient. The product may provide

significant benefit over the standard of care and targets a well-defined

and severely ill patient population. Mipomersen is currently being

studied in a Phase 3 clinical trial involving patients with homozygous

familial hypercholesterolemia.

This press release contains forward-looking statements regarding Genzyme's financial outlook and business plans and strategies, including without limitation: its Q2 2008, YE 2008 and YE 20011 earnings guidance; its anticipated CAGR through 2011; its expectations for approval of Myo
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... Matrix Marketing Group, LLC ... has hired Gem Swartz to head up its account management department as vice president ... Gem and Amanda bring senior account management and delivery expertise to the growing Matrix ...
(Date:6/30/2015)... June 30, 2015  The Dr. Samadi Prostate Cancer Center ... offering a full suite of new genetic testing methods for ... for diagnosing prostate cancer. Dr. Samadi,s ... tests for assessing the risk and optimizing the diagnosis of ... very excited to now offer these revolutionary genetic tests to ...
(Date:6/29/2015)... (PRWEB) , ... June 30, 2015 , ... This cutting ... Perkin Elmer machines. Featuring 12 distinct peaks, the WAV-8 is the world’s first ... is in spec deep into the NIR range. Previous spectrophotometer calibration standards, such as ...
(Date:6/29/2015)... DIEGO , June 29, 2015 BioNano ... group of top research institutes, announced today that a ... Mount Sinai resulted in the creation of the first ... complementary single DNA molecule methods for sequencing and genome ... , provided the comprehensive analysis of the contiguous diploid ...
Breaking Biology Technology:Matrix Marketing Group Expands Client Services Team 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 3BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 2BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 3
... FOLD ) today announced that John Crowley, President and ... Merrill Lynch,Global Pharmaceutical, Biotech & Medtech 2007 Conference in ... BDT (11:00 am EDT) at the,Merrill Lynch Financial Centre. ... will be available to all,interested parties through the Investors ...
... a,biotechnology company translating the complexity of human biology ... president and,CEO, Dr. Keith O. Elliston, has been ... in Arlington, Va., September 17-18. Dr. Elliston ... Development and Commercial Value Added in Care Delivery ...
... ... and Reusable Bottles, MONROVIA, Calif., Sept. 12 Bottled or ... of consumers who fear the impact of,bottled water on the environment, ... assembled a family of products on its website, http://www.discovertesting.com, in ...
Cached Biology Technology:Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference 2Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference 3Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit 2Discover Testing Settles the Drinking Water Debate: Tap vs. Bottled 2
(Date:6/23/2015)... June 22, 2015 ... addition of the "Body-Worn Temperature Sensors Market ... and Forecast 2014 - 2020" report to ... analysis of the global body-worn temperature sensors market. ... segmented on the basis of types, care setting, ...
(Date:6/18/2015)... Conn. , June 18, 2015 NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market announces ... a featured segment on "Money on the Mark", scheduled to ... City June 20 th . ... will be from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO ...
(Date:6/17/2015)... , June 17, 2015  Crossmatch™, a leading ... that its U.are.U ® 4500 fingerprint readers ... Eateries, Inc., a San Jose, ... to increase security, improve accountability and reduce fraud ... instant, non-repudiable identity confirmation for employee sign in ...
Breaking Biology News(10 mins):Body-Worn Temperature Sensors Market - Global Industry Analysis 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3
... today announced that it will launch EMBO Press on ... for The EMBO Journal , EMBO reports , ... provides opportunities for the future development of the journals. ... to encourage transparency in the publication process and help researchers make ...
... is derived from brain tumor stem cells, the source ... unclear. The potential of neural stem cells to transform ... but has not been confirmed. A team led by ... Nanjing Medical University, China found that doxycycline-induced neural stem ...
... Queen,s University Belfast is a lead partner in a ... new ways to treat Cystic Fibrosis. Affecting more ... is one of the most common life-threatening inherited diseases. ... death for patients., The new global programme, known as ...
Cached Biology News:EMBO announces the launch of EMBO Press 2Queen's University in €6m bid to find new Cystic Fibrosis treatments 2Queen's University in €6m bid to find new Cystic Fibrosis treatments 3
... consumable measurement plate for QPatch. ... controlled measurement sites. Each measurement ... flow channel system that enables ... and compound applications necessary for ...
This bispecific antibody complex has been tested for efficient depletion of CD41+ cells using the StemSep ; negative immunomagnetic cell separation system....
... to supply microplates, deepwells, and tips to ... in mind, iLink incorporates multiple functions into ... iLink software is the key to building ... can be copied and installed as turnkey ...
No-Weigh Dithiothreitol (DTT) ,7.7 mg DTT/Tube x 48 tubes...
Biology Products: